SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is experiencing significant volatility and downward pressure as investors navigate a combination of bearish short-seller reports and broader macroeconomic concerns. The community remains deeply divided, with some actively accumulating shares during the dip based on insider buying, while others express frustration over persistent share dilution and the stock's failure to maintain momentum alongside the broader market.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is seeing intense investor focus fueled by a flurry of strategic acquisitions, including Rotron Aerospace and 4M Defense, alongside a high-profile partnership with Palantir that has bolstered its status as an emerging defense prime. While the stock experiences significant intraday volatility and selling pressure attributed to warrant-related hedging, the community remains heavily bullish, fixated on the upcoming earnings report and the company's potential to secure major government defense contracts in an increasingly autonomous and drone-centric global threat landscape.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is experiencing extreme volatility driven by a massive insider share purchase by the CEO and growing investor anticipation regarding a potential partnership with OpenAI. The community remains deeply divided, with some traders viewing these catalysts as a long-term bottoming signal, while others criticize the company's executive compensation and struggle to reconcile the positive news with the stock's persistent intraday sell-offs.

Swarmer, Inc. is an AI-driven software company, which develops software platforms and AI systems for autonomous swarm control of drones and unmanned vehicles. The firm offers STYX AI Command and Control System, MINAS Autonomy and Collaboration AI, and TRIDENT Embedded Drone Operating System. The company was founded by Alex Fink and Serhii Kuprienko in May 2023 and is headquartered in Austin, TX.

Swarmer Inc.

Swarmer Inc. is experiencing a volatile and high-momentum market debut as investors speculate on its drone autonomy software, which has gained attention for its reported real-world combat application. The community remains sharply divided, with some betting on a parabolic "low-float" squeeze driven by defense industry demand, while others caution against potential hype-driven instability and speculative valuations.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending as the community highlights recent long-term clinical data showing Briumvi's high efficacy and record-low relapse rates, fueling speculation about potential buyouts or increased market share. Investors are actively discussing the stock's growth potential versus its current price suppression, while closely watching for upcoming earnings and subcutaneous treatment updates.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology is facing heightened volatility as traders weigh strong product milestones in AI data center infrastructure against recent insider selling and broader market rotation out of high-growth semiconductor plays. The community is actively debating the stock's future, with many interpreting recent sharp price swings as manipulative shakeouts while bulls focus on the company's long-term potential in AI connectivity.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as investors weigh strong demand for its GLP-1 franchise against intense market competition and analyst downgrades regarding valuation and addressable market size. The community remains highly focused on the company's upcoming pipeline catalysts, specifically the anticipated approval of its oral weight-loss drug, while debating whether recent share price volatility represents a buying opportunity or a correction from previous overvaluation.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is rallying toward all-time highs as investors pile in ahead of quarterly earnings, driven by intense demand for high-bandwidth memory (HBM) and recent announcements regarding significant manufacturing expansions in Taiwan. The community is heavily focused on the company's critical role in the AI infrastructure supply chain, with active debates centered on whether the stock remains undervalued despite its massive run or if it faces a potential post-earnings pullback.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending following a massive $27 billion AI infrastructure deal with Meta, which effectively cements its status as a leading hyperscaler. While the stock initially surged, it faced downward pressure due to the announcement of a $3.75 billion convertible senior notes offering, sparking intense debate among investors over whether the move represents necessary capital-intensive growth or dilutive overreach.

Talon Metals Corp. engages in the exploration and development of mineral properties. It holds interests in the Tamarack nickel-copper-cobalt and Trairão iron projects. The company was founded on April 5, 2005 and is headquartered in Road Town, British Virgin Islands.

Talon Metals Corp

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Stock Index Futures Climb on Trump Tariffs Report, U.S. PPI Data and Fed Speak in Focus

March S&P 500 E-Mini futures (ESH25) are up +0.49%, and March Nasdaq 100 E-Mini futures (NQH25) are up +0.67% this morning as a report indicating the U.S. might take a gradual approach to hiking tariffs boosted sentiment, while investors awaited crucial producer inflation data and comments from Federal Reserve officials.

Intra-Cellular Therapies' stock (ITCI) surged over 35% in premarket trading on Monday, poised for its best-ever open and a record high, even as broader market futures grappled with weak tech stock performance.&nbsp;The biotech firm announced it would be acquired by Johnson &amp; Johnson (JNJ) in a $14.6 billion cash deal, valuing ITCI shares at $132 each,&nbsp;which represents about 40% premium to previous close.The transaction, funded through a mix of cash and debt, is expected to close later this year, subject to shareholder and regulatory approvals. Once completed, ITCI shares will be delisted from the Nasdaq.&nbsp;Johnson &amp; Johnson plans to maintain its capital allocation strategy, including R&amp;D investment, dividends, and strategic share buybacks.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ITCI_sentiment_and_message_volume_Jan_13_premarket_42a2cd35bb.png" alt="ITCI sentiment and message volume Jan 13 premarket.png" width="1318" height="324"><figcaption>ITCI sentiment and message volume Jan 13 premarket as of 7:40 am ET | source: Stocktwits</figcaption></figure>Following the announcement, sentiment for ITCI on Stocktwits turned 'extremely bullish,' and the stock became one of the platform's top 20 trending symbols.&nbsp;Some retail investors speculated that J&amp;J secured a bargain deal amid a flurry of positive chatter.<stembedurl>https://stocktwits.com/manymore/message/599736216</stembedurl><stembedurl>https://stocktwits.com/megamaven/message/599767133</stembedurl>Shares of J&amp;J, meanwhile, were flat premarket Monday following a more than 2% dip over the last week, with retail sentiment on Stocktwits turning 'bullish.’ITCI's flagship product, Caplyta, is a once-daily oral therapy approved for treating schizophrenia and depressive episodes linked to bipolar disorders, which reportedly raked in sales of $464 million in 2023.The company recently reached a favorable patent settlement with Sandoz, ensuring no generic Caplyta will launch until 2040. Analysts at BofA Securities raised ITCI's price target to $118 on Sunday, citing the settlement's positive implications.<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/32a4bb19-5f28-4ea7-a9c8-a776ef2fecd9">According</a> to the Financial Times, the deal highlights J&amp;J's strategic response to looming patent cliffs, including its projected $17 billion revenue loss when its Darzalex treatment for rare blood cancers loses exclusivity in 2029.The report added that the acquisition marks a bright spot for the biotech sector, which saw M&amp;A activity plunge in 2024. Pharma companies spent $45 billion across 30 deals — nearly half the prior year's total.ITCI stock gained 12.7% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Intra-Cellular Therapies Stock Shines Amid Market Slump On J&J’s $14.6B Buyout Deal: Retail Brims With Optimism

ITCI's flagship product, Caplyta, is a once-daily oral therapy approved for treating schizophrenia and depressive episodes linked to bipolar disorders, which reportedly raked in sales of $464 million in 2023.

Equity

J&J explores takeover bid for Intra-Cellular Therapies, Bloomberg reports

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in Bedminster, NJ.

ITCI
Intra-Cellular Therapies Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ITCI News

ITCIIntra-Cellular Therapies Inc